Emerging data suggest this peptide, a dual agonist targeting both GLP-1 and GIP , could represent a notable step forward for obesity management . Early human trials have shown substantial decreases https://getretatrutideaustralia.com/blog/retatrutide-vs-tirzepatide-semaglutide